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ABSTRACT
Objective: To determine the diagnostic values of digital rectal examination (DRE), 
prostate specific antigen (PSA) and trans-rectal ultrasound (TRUS) individually and 
in combinations in men aged 50 years and above presenting with prostatism. 
Design: A prospective, descriptive, cross-sectional, hospital-based study. 
Setting: The urology ward of Kilimanjaro Christian Medical Centre (KCMC), a 500 
bed tertiary hospital in the Kilimanjaro region, Tanzania. 
Subjects: Ninety four consecutive admissions of men aged 50 years and above admitted 
with urinary symptoms suggestive of prostatism. 
Main outcome measures: Primary outcome measures included race and age of patient; 
Positive predictive values, sensitivities and specificities for DRE, PSA and TRUS 
individually and in combinations and histology of the prostate specimens submitted 
after Tru-cut, TURP or open prostatectomy. The secondary outcome measures were 
mean PSA and PSA density. 
Results: There was a prostate adenocarcinoma incidence of 25.5%; all found among 
patients with PSA levels greater than 10ng/ml. The positive predictive value (PPV), 
sensitivity and specificity of DRE for prostate cancer were 0.67%, 66.7% and 88.6% 
with an accuracy of 82.8%; while for TRUS, the respective values were 0.58%, 58.3% 
and 85.7% with an accuracy of 78.7%. PSA alone had a positive predictive value of 
0.16. A combination of abnormal DRE and PSA (more than 4.0ng/ml) had a positive 
predictive value (PPV) of 0.75 while when DRE, TRUS and PSA were all abnormal, 
the PPV rose to 0.80. 
Conclusion: A combination of DRE and PSA yields 75% diagnostic sensitivity for 
prostate cancer and is reliable enough to exempt TRUS where not available since it 
only adds 5% to this strong diagnostic combination. 
INTRODUCTION
The World Health Organisation (WHO) recommends 
standard diagnostic tests in patients presenting 
with lower urinary tract symptoms (LUTS) 
suggestive of prostatism. Besides the International 
Prostate Symptoms Score (IPSS) and urodynamic 
evaluations, these include adequate medical 
history, focused physical including digital rectal 
examination and serum prostate specific antigen 
(PSA) with trans-rectal ultrasound (TRUS) as an 
optional complimentary study. In resource limited 
settings as in Africa, one would be interested in 
ascertaining the reliability of the means available 
for dependable diagnosis. Regional differences also 
call for local data that is to date missing in the East 
African region. 
 Race, age and size of the prostate influence 
significantly the prostate specific antigen (PSA) value 
(2,3) yet PSA rise among men with either normal or 
abnormal digital rectal examination (DRE) findings 
suggests likely malignancy and adds important 
information to that of  DRE regarding the risk of cancer 
presence. Histology remains the gold standard in 
reaching a conclusive diagnosis in patients presenting 
with prostatism. 
 The combined value of DRE, PSA and TRUS for 
detection of prostate cancer has been demonstrated 
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in the developed world but local data is sorely 
missing. This study was an attempt at addressing 
the local deficit with reference to published data in 
the diagnosis of patients with prostatism and will 
hopefully inform the approach to patients with 
prostatism in our region. 
MATERIALS AND METHODS
A total of 94 consecutive men aged 50 years and 
above admitted with prostatism to the Urology 
ward of the Kilimanjaro Christian Medical Centre 
(KCMC),  Moshi, were recruited into the study upon 
consenting. 
 Detailed presentation and medical history were 
taken, followed by a thorough physical (including 
digital rectal) examination and a focused neurological 
examination aimed at assessing the anal sphincteric 
tone, bulbocarvenous reflex and sensori-motor 
function of the lower extremeties. During DRE, the 
shape, size and consistency of the prostate gland 
were determined and recorded. DRE was considered 
abnormal when the gland exhibited an induration, 
nodules, asymmetry, irregularity or fixity of overlying 
rectal mucosa. 
 Two millilitres of whole blood were taken for 
PSA assays. Serum was separated within 24 hours, 
and stored at -80°C as per the recommendations of 
the kit in use. 
 Serum total PSA value of each sample was 
determined by PATHOZYME Prostate Specific 
Antigen Ref 00 327, Omega Diagnostic (UK). PSA 
values below 4ng/ml were considered normal while 
those in excess of this were adjudged abnormal on 
the basis of the PATHOZYME kit specifications. 
Samples were coded and analysed within a week of 
collection. 
 All recruited men were subjected to TRUS using 
Aloka SSD 650 Echo Camera equipped with a 7.5 
MHz transducer probe; with the patient in the left 
lateral decubitus position and full flexion of both 
hip and knee joints. A well lubricated probe covered 
with a condom was introduced rectally, scanning 
the prostate gland in axial and sagital planes. The 
prostate contours were mapped and the prostate 
volume, including intra-vesicle extensions, was 
recorded. Special attention was focused on presence 
of hypo-echoic lesions within the prostate, breach of 
the overlying capsule and any changes involving the 
seminal vesicle. Presence of these features qualified 
as abnormal TRUS findings. 
 Patients with suspicious or abnormal nodules on 
DRE were subjected to trans-rectal digitally guided 
lesion biopsy using a standard 18 gauge needle 
loaded in a spring driven gun without any form of 
anaesthesia. Systematic sector biopsies were taken to 
a total six core biopsies. All patients got Ciprofloxacin 
500mg orally twice a day and Metronidazole 400mg 
orally thrice a day for five days, and Diclofenac 50mg 
orally thrice daily or Paracetamol 1 gm orally thrice 
a day for three days after the procedure.  
 The tru-cut biopsies, prostate chips recovered 
during trans-urethral resection of prostate (TURP) and 
glands enucleated during retro-pubic prostatectomy 
of recruited patients were submitted for histological 
analysis. This was the gold standard test. 
 A structured questionnaire was used to collect 
information including the patients’ age, symptoms, 
digital rectal examination findings, prostate size and 
trans-rectal ultrasound (TRUS) findings, prostate 
specific antigen values and histology results. 
 Statistical analysis using Statistical Package 
for Social Sciences (SPSS) version 11.5 software 
included correlations, determination of positive 
predictive value, sensitivity and specificity. Tests 
were considered significant if less than 0.05. 
RESULTS
All the 94 patients were blacks. Their age range was 
50-93 years; a mean of 73 years. The majority (44.2%) 
were in the 70-79 years age group (Figure 1). 
Figure 1
Age distribution of patients with prostatism
Twenty four patients (25.5%) were found to have 
prostate cancer on histology; the rest had benign 
prostate hyperplasia (BPH). Twenty four were found 
to have abnormal DRE findings. Out of these, 16 had 
prostate cancer, giving a positive predictive value 
of 0.67. Seventy patients were considered to have 
normal DRE results but eight of these had prostate 
cancer. The sensitivity and specificity for DRE were 
66.7% and 88.6% respectively. An abnormal digital 
rectal examination, therefore, had a diagnostic value 
of 67%. 
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 None of the patients diagnosed to have cancer 
of the prostate had PSA levels less than 10ng/ml. 
These patients had a significantly higher mean PSA 
and prostate specific antigen density (PSAD) than 
of patients with benign prostate disease (p values of 
0.036 and 0.035 respectively). The youngest of them 
was 53 years old. An isolated abnormal prostate 
specific antigen with the rest of the findings normal 
had a diagnostic value of 16%. 
 A total of 24 patients showed abnormal TRUS 
findings out of which 14 were found to have prostate 
cancer. The positive predictive value was 0.58. Out of 
the 70 patients adjudged to have normal TRUS results, 
10 had prostate cancer. The sensitivity and specificity 
of TRUS was 58.3% and 85.7% respectively. The 
individual diagnostic value of trans-rectal ultrasound 
was 58%. 
 The three means of diagnosis were analysed in 
combinations to ascertain their combined diagnostic 
values. Patients who had normal PSA (<4ng/ml) but 
subjectively thought to have abnormality in both 
DRE and TRUS had no significant correlation with 
prostate cancer. A PSA in excess of 4ng/ml but less 
than 10ng/ml with normal DRE and TRUS findings 
showed a positive predictive value of 0.16 for prostate 
cancer. A combination of abnormal PSA and DRE 
had a positive predictive value of 0.75. When all the 
variables (PSA, DRE and TRUS) were abnormal, the 
positive predictive value rose to 0.8 (Figure 2). 
DISCUSSION
Twenty five point five per cent of the patients 
evaluated had adenocarcinoma of the prostate. 
This rate is lower than that previously found by 
Nassanga (4) with a rate of 32.5% but compares well 
with findings by Men et al (5) in Turkish men with 
a rate of 23.1%. The difference in the detection rate 
might be due to use of different methods of biopsy 
collection. In the Nassanga series, all patients were 
subjected to systematic six core biopsies regardless of 
DRE findings, with digitally directed needle biopsies 
in patients with palpable nodules. In contrast, in this 
study, the majority of the biopsies (78 specimens) 
were prostate chips obtained after trans-urethral 
resection of prostate (TURP) with enucleated glands 
after retro-pubic prostatectomy and digitally directed 
needle biopsies in those with grossly discern able 
pathology accounting for the remaining 16 samples. 
During TURP, the peripheral zone which harbours 
about 70% of prostate cancer may not be adequately 
sampled and this may account for the differences in 
the detected numbers of prostate cancer. 
 Digital rectal examination had a positive 
predictive value of 0.67 and specificity of 88.6%. In a 
European study by de Reijke et al (6) on patients with 
prostatism, the positive predictive value was 0.48, 
suggesting geographical differences on the predictive 
value of DRE in evaluation of men with prostatism. 
Figure 2
The positive predictive values of diagnostic modes in combination
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 The PSA values found in this study group are 
relatively high with none of the cancer cases having 
PSA levels less than 10 ng/ml; unlike in the developed 
countries where cancer of the prostate has been found 
in patients with PSA values as low as 1.1 ng/ml (7) 
and debate is on to push down the cut off point to 
values below 4.0ng/ml with respect to, particularly, 
age and race of the patient (8,9); the size of the prostate 
as well as non-neoplastic causes of PSA elevation like 
inflammation and recent instrumentation require the 
prostate specific antigen (PSA) density and the PSA 
velocity respectively to ascertain malignancy. Studies 
done elsewhere have highlighted the PSA difference 
among races with Africans having higher levels 
than Arabs whose PSA levels are in turn higher than 
for Caucasians (6, 10) mainly because of the racial 
differences in prostate sizes and levels of testosterone 
produced. 
 The positive predictive value and overall 
accuracy of TRUS were both lower than for DRE. 
Generally, TRUS use in the diagnosis of prostate cancer 
has such limitations as interpretation difficulties of 
suspicious hypo-echoic lesions that is user dependent. 
In this study, the tru-cut prostate biopsies were not 
TRUS guided and this may have contributed further 
to the limited value for TRUS in the diagnosis. 
 Digital rectal examination (DRE) and trans-
rectal ultrasound (TRUS) rely on subjective analysis 
that depends on experience. Prostate specific 
antigen (PSA) estimation is more objective than 
both DRE and TRUS. With delays in presentation 
as occurs in our setting, the DRE predictive value 
becomes better than in localities where patients 
present earlier. Seen in totality, the best combination 
of these means of diagnosing prostate cancer 
are DRE and PSA. The addition of TRUS to this 
combination has a limited advantage that in resource 
deficient countries can be dispensed with without 
significant compromise on the diagnostic process. 
This finding of our study is in line with the World 
Health Organisation (WHO) suggestion that DRE 
and PSA be used as complementary tests and TRUS 
be considered optional in the primary evaluation 
of men with prostatism (1). These two assessment 
modes should be an integral part in the evaluation 
of patients presenting with prostatism in our local 
setting of East Africa given that they give a predictive 
value of 0.75 in this study and abnormal TRUS adds 
only 0.05 to this predictive value. 
In conclusion, the PSA levels in the local African 
population are strikingly higher than in the European 
studies and the cases histologically confirmed to be 
prostate cancer were all beyond 10ng/ml. 
A combination of DRE and PSA yields 75% diagnostic 
sensitivity for this malignancy and are reliable enough 
to exempt TRUS where not available since it only adds 
5% to this strong diagnostic combination. 
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